 |
 |
PharmaVOICE - September 2009 The Knowledge Revolution By Denise Myshko In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients,” will be common. These simulations will speed experimentation and help predict safety and efficacy of new medicines for each patient. Researchers and patients will gain access to greater computing power, new user interfaces, and miniature biomonitors that continuously collect data. Sound like science fiction? Not to Jonathan Peck. His organization, the Institute for Alternative Futures, predicts there will be a knowledge revolution in the decades ahead that transcends the information revolution of the past two decades. The accelerating spread of knowledge combined with advanced technology will create widespread changes to healthcare and how new medicines are developed. Mr. Peck, president of the Institute, and other industry experts predict there will be a digital convergence of many of the technologies that are just beginning to take hold in the pharmaceutical industry, including genomics, artificial intelligence, virtual reality... Sidebars: Seven Recommendations for Planning for the Future 2029: What’s to Come Key Trends Now Emerging and Their Implication for Pharma Experts on this topic Lee Babiss, Ph.D. Global Head of Pharma Research, Roche, one of the world’s leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more information, visit roche.com. Alex L. Bangs. Co-founder and Chief Technology Officer, Entelos Inc., a life-sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and used. For more information, visit entelos.com. Carolyn Buck Luce. Global Life-Science Sector Leader, Ernst & Young, a global leader in assurance, tax, transaction, and advisory services. For more information, visit ey.com. Deborah Dunsire, M.d. President and CEO, Millennium: The Takeda Oncology Company, a wholly owned, independent subsidiary of Takeda Pharmaceutical Co. Ltd. with a robust pipeline of drug candidates being investigated in a broad range of cancers. For more information, visit millennium.com. Glenn Gormley, M.D., Ph.D. President, Daiichi Sankyo Pharma Development, the product development arm of the U.S. organization Daiichi Sankyo Inc., which is engaged in clinical development, translational medicine and clinical pharmacology, regulatory affairs and risk management, informatics and knowledge management, biostatistics and data operations, and development research. For more information, visit dsi.com/research/pharmadev.html. Alice Jacobs, M.D. Founder, Chairman, and CEO, IntelligentMDx, a molecular diagnostics company developing proprietary nucleic acid (DNA or RNA) diagnostic solutions for a wide range of human diseases. For more information, visit intelligentmdx.com. Neil Patel, Pharm.D. Director of Pharmaceutical Research and Development Operations, PricewaterhouseCoopers, which provides industry-focused assurance, tax, and advisory services to build public trust and enhance value for its clients and their stakeholders. For more information, visit pwc.com. Jonathan Peck. President, Institute for Alternative Futures (IAF), a nonprofit research and educational organization that specializes in aiding organizations and individuals to more wisely choose and create their preferred futures. He is also president of IAF’s for-profit subsidiary, Alternative Futures Associates (AFA). For more information, visit altfutures.com. Arun Ravi. Healthcare Consultant, Frost & Sullivan, which enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. For more information, visit frost.com. Lynn O’Connor Vos. CEO, Grey Healthcare Group (GHG), a WPP company and a healthcare communications group. For more information, visit ghgroup.com.
|
